logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yoshihisa Tokumaru

Gifu University Hospital
H指数:32
被引数:3,112

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Central nervous system symptom burden and clinical implications for antiemetic management with olanzapine in AC chemotherapy

中枢神经系统症状负担及奥氮平在AC化疗中抗恶心管理的临床意义

Oncologist
IF4.2
2026-09-090
OAAI
Ryoko Udagawa; Mototsugu Shimokawa; Hirotoshi Iihara; Rie Ozeki; Michiko Tsuneizumi; Manabu Futamura; Tomoyuki Fujita; Hideaki Ogata; Hiroko Bando; Toshitaka Uomori; Hironobu Hashimoto; Ryosuke Hayami; Yoshihisa Tokumaru; Goro Kutomi; Kan Yonemori; Ryoichi Matsunuma; Mika Kitahora; Naotake Yanagisawa; Tatsunori Shimoi; Mitsue Saito; null
Decreased Expression by a Chemically Modified siRNA to PTBP1 Seriously Affects Warburg Effect in Colorectal Cancer Cells

化学修饰的siRNA对PTBP1表达的降低严重影响了结直肠癌细胞中的瓦博格效应

Cancer Science
IF4.3
2026-08-180
OAAI
Keita Matsumoto; Hirokatsu Hayashi; Yoshihisa Tokumaru; Seito Fujibayashi; Noriki Mitsui; Masahide Endo; Takeshi Horaguchi; Yuji Hatanaka; Ryoma Yokoi; Chika Mizutani; Masashi Kuno; Masahiro Fukada; Ryuichi Asai; Itaru Yasufuku; Yuta Sato; Jesse Yu Tajima; Yoshihiro Tanaka; Remi Nakashima; Yukihiro Akao; Nobuhisa Matsuhashi
Correction: Tokumaru et al. High Expression of microRNA-143 Is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer. Int. J. Mol. Sci. 2020, 21, 3213

更正：Tokumaru等人。微RNA-143高表达与雌激素受体阳性乳腺癌中肿瘤免疫微环境的良好状态及更好的生存率相关。Int. J. Mol. Sci. 2020, 21, 3213

International Journal of Molecular Sciences
IF4.9
2026-08-010
OA
Yoshihisa Tokumaru; Mariko Asaoka; Masanori Oshi; Eriko Katsuta; Li Yan; Sumana Narayanan; Nobuhiko Sugito; Nobuhisa Matsuhashi; Manabu Futamura; Yukihiro Akao; Kazuhiro Yoshida; Kazuaki Takabe
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

日本 (KBCSG-TR-1316) 检测激素受体阳性HER2-negative晚期和转移性乳腺癌对CDK4/6抑制剂耐药的高危患者

BREAST CANCER
IF2.9
2023-07-243
OAAI
Futamura, Manabu; Nakayama, Takahiro; Yoshinami, Tetsuhiro; Oshiro, Chiya; Ishihara, Mikiya; Morita, Midori; Watanabe, Akira; Tanigichi, Azusa; Tsukabe, Masami; Shimoda, Masafumi; Nitta, Kanae; Chihara, Yoko; Yasojima, Hiroyuki; Ouchi, Yoshimi; Tokumaru, Yoshihisa; Masuda, Norikazu
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)
BREAST CANCER
IF2.9
2023-01-073
OAAI
Futamura, Manabu; Ishihara, Kazuhiro; Nagao, Yasuko; Ogiso, Atsuko; Niwa, Yoshimi; Nakada, Takumi; Kawaguchi, Yoshihiro; Ikawa, Ai; Kumazawa, Iwao; Mori, Ryutaro; Kitazawa, Mai; Hosono, Yoshiki; Kuno, Masashi; Kawajiri, Mana; Nakakami, Akira; Takeuchi, Makoto; Morikawa, Akemi; Tokumaru, Yoshihisa; Katagiri, Yasuo; Asano, Yoshimasa; Mushika, Yoshinori; Shimokawa, Toshio; Matsuhasih, Nobuhisa

研究方向

暂未获取到该数据
K
Kazuaki Takabe
H 指数:70论文数:735被引数:1.7万
M
Masanori Oshi
H 指数:37论文数:218被引数:4,000
M
Manabu Futamura
H 指数:30论文数:242被引数:3,538
Li Yan 封面图
Li Yan
H 指数:54论文数:295被引数:9,310
K
Kazuhiro Yoshida
H 指数:54论文数:723被引数:1.4万
R
Rongrong Wu
H 指数:23论文数:106被引数:2,333
T
Takashi Ishikawa
H 指数:57论文数:758被引数:1.4万
I
Itaru Endo
H 指数:83论文数:1,406被引数:3.3万
M
Mariko Asaoka
H 指数:29论文数:105被引数:2,590
R
Ryusei Matsuyama
H 指数:45论文数:283被引数:6,106